Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suven Life Sciences reported FY2026 standalone revenue of Rs 711.47 lakhs, up 6.9% from Rs 665.58 lakhs in FY2025. However, the company recorded a standalone net loss of Rs 5,486.28 lakhs, worsening from Rs 4,707.98 lakhs in the prior year. On a consolidated basis, the loss was significantly higher at Rs 27,634.41 lakhs due to massive R&D expenses of Rs 24,818.81 lakhs (vs Rs 14,396.18 lakhs previously) in the US subsidiary Suven Neurosciences Inc. The company raised Rs 76,432.53 lakhs through preferential warrant conversions, with Rs 26,068.64 lakhs utilized so far. Cash and bank balances remain strong at Rs 51+ crores. The Board also noted fines from BSE/NSE for past compliance lapses and advised better regulatory adherence.
Heavy R&D investment continues to drive losses, but strong cash reserves from the preferential issue provide runway. The stock may remain under pressure due to persistent losses despite modest revenue growth.